CRISPR-Cas9 screening identifies INTS3 as an anti-apoptotic RNA-binding protein and therapeutic target for colorectal cancer

  • iScience. 2024 Apr 6;27(5):109676. doi: 10.1016/j.isci.2024.109676.
Zhiwei Wang  1 Cheng Zhang  1 Jing Guo  1 Yanmei Yang  2 Peixian Li  1 Ziyan Wang  1 Sijia Liu  1 Lulu Zhang  1 Xiaoyu Zeng  1 Jincheng Zhai  1 Xinyong Wang  1 Qi Zhao  3 Zhenzhen Chen  1 Pingping Zhu  1 Qiankun He  1
Affiliations
  • 1. School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001, China.
  • 2. Research Center of Basic Medicine, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • 3. Department of oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Abstract

Growing evidences indicate that RNA-binding proteins (RBPs) play critical roles in regulating the RNA splicing, polyadenylation, stability, localization, translation, and turnover. Abnormal expression of RBPs can promote tumorigenesis. Here, we performed a CRISPR screen using an RBP pooled CRISPR knockout library and identified 27 potential RBPs with role in supporting colorectal Cancer (CRC) survival. We found that the deletion/depletion of INTS3 triggered Apoptosis in CRC. The in vitro experiments and RNA Sequencing revealed that INTS3 destabilized pro-apoptotic gene transcripts and contributed to the survival of CRC cells. INTS3 loss delayed CRC cells growth in vivo. Furthermore, delivery of DOTAP/cholesterol-mshINTS3 nanoparticles inhibited CRC tumor growth. Collectively, our work highlights the role of INTS3 in supporting CRC survival and provides several novel therapeutic targets for treatment.

Keywords
Cancer; Molecular biology.